Determinants of Autism Spectrum Disorder

Background: Autism spectrum disorder (ASD) now affects more than one in 31 children in the United States, with prevalence rising sharply over recent decades. ASD is recognized as a complex neurodevelopmental disorder shaped by genetic, environmental, and iatrogenic influences. Clarifying the contribution of these determinants is critical to addressing the escalating public health burden.

Methods: We comprehensively examined epidemiologic, clinical, and mechanistic studies evaluating
potential ASD risk factors, assessing outcomes, exposure quantification, strength and independence of
associations, temporal relationships, internal and external validity, overall cohesiveness, and biological plausibility.

Results: Key determinants of new-onset ASD before age nine include advanced parental age, premature delivery, genetic variants, sibling recurrence, maternal immune activation, in utero drug exposure, environmental toxicants, gut–brain axis disruption, and cumulative routine childhood vaccination. These factors may converge through pathways such as immune dysregulation, mitochondrial dysfunction, and neuroinflammation, which may contribute to neurodevelopmental injury in susceptible children. Of 136 studies examining childhood vaccines or their excipients, 29 found neutral risks or no association, while 107 inferred a possible link between immunization or vaccine components and ASD or other neurodevelopmental disorders (NDDs), based on findings spanning epidemiologic, clinical, mechanistic, neuropathologic, and case-report evidence of developmental regression. 12 studies comparing fully vaccinated and completely unvaccinated populations consistently showed superior overall health outcomes among the unvaccinated, including significantly lower risks of chronic disease and neuropsychiatric disorders such as ASD. The neutral association papers were undermined by absence of a genuinely unvaccinated control group, registry misclassification, ecological confounding, and averaged estimates that obscure effects within vulnerable subgroups. We observed strong, consistent increases in cumulative vaccine exposure during early childhood and the reported prevalence of autism across successive birth cohorts. To date, no study has evaluated the safety of the entire cumulative pediatric vaccine schedule for neurodevelopmental outcomes through age 9 or 18 years.

Conclusion: The totality of evidence supports a multifactorial model of ASD in which genetic predisposition, neuroimmune biology, environmental toxicants, perinatal stressors, and iatrogenic exposures converge to produce the phenotype of a post-encephalitic state. Combination and early-timed routine childhood vaccination represents a significant modifiable risk factor for ASD within a broader multifactorial framework, supported by convergent mechanistic, clinical, and epidemiologic findings, and characterized by intensified use, the clustering of multiple doses during critical neurodevelopmental windows, and the lack of research on the cumulative safety of the full pediatric schedule. As ASD prevalence continues to rise at an unprecedented pace, clarifying the risks associated with cumulative vaccine dosing and timing remains an urgent public health priority.

Keywords: Autism, autism spectrum disorder, neurodevelopmental disorder, vaccine, vaccination, determinants, risk factors